Dermatitis
MONDO:0002406An inflammatory process affecting the skin. Signs include red rash, itching, and blister formation. Representative examples are contact dermatitis, atopic dermatitis, and seborrheic dermatitis.
Also known as: inflammation of skin, inflammation of the skin, inflammation of zone of skin, inflammatory skin disease, skin inflammation, zone of skin inflammation
1411 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Eczema drug study halted early: what we learned about GSK1070806
Disease control TerminatedThis study was designed to check the long-term safety of an experimental drug called GSK1070806 for people with moderate to severe eczema (atopic dermatitis). It enrolled 79 adults who had already completed an earlier study of the same drug. The study was terminated early, so res…
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can an extra shot boost COVID protection in autoimmune patients?
Disease control TerminatedThis study tests whether an additional dose of a COVID-19 vaccine can improve immune protection in adults and children with autoimmune diseases like rheumatoid arthritis, lupus, multiple sclerosis, and others who are taking immunosuppressive medications. Participants who had a we…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Eczema drug trial halted early – what we know
Disease control TerminatedThis study tested an experimental drug called JNJ-95475939 in 256 adults with moderate to severe atopic dermatitis (eczema). The goal was to see if the drug could improve skin symptoms like redness, itching, and scaling better than a placebo. The trial was stopped early, so final…
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New Two-Target antibody for eczema tested in early trial
Disease control TerminatedThis early-stage trial tested a new drug called NM26-2198, a bispecific antibody that blocks two inflammatory signals (IL-4R and IL-31) involved in atopic dermatitis (eczema). The study included 126 healthy volunteers and patients with moderate-to-severe eczema, receiving either …
Phase: PHASE1 • Sponsor: Yellow Jersey Therapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Eczema drug trial halted midway – what happened?
Disease control TerminatedThis study tested an injectable drug called GSK1070806 in 161 adults with moderate to severe atopic dermatitis (eczema) who had already tried other treatments. The goal was to see if the drug could reduce eczema severity and itching compared to a placebo. However, the trial was t…
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Eczema drug switch studied after first treatment fails
Disease control TerminatedThis study looked at whether a drug called tralokinumab could help adults with eczema who had already tried dupilumab and didn't get enough relief. The plan was to treat 20 people for 24 weeks, but the study was stopped early and only 7 people took part. The main goal was to see …
Phase: PHASE4 • Sponsor: Psoriasis Treatment Center of Central New Jersey • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New cream aims to stop vitiligo relapse after repigmentation
Disease control TerminatedThis trial tested a cosmetic cream called RV5098A to see if it could help adults with vitiligo keep their facial pigmentation after successful repigmentation treatment. Vitiligo causes white patches on the skin, and even after treatment, about 40% of people lose color again withi…
Sponsor: Pierre Fabre Dermo Cosmetique • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Eczema probiotic trial for kids ends early – too few participants
Disease control TerminatedThis study tested a probiotic supplement for children aged 6 months to 3 years with mild-to-moderate eczema. The goal was to see if the probiotic could reduce eczema severity and the need for steroid creams. However, the trial was terminated early and only enrolled 4 children, so…
Phase: NA • Sponsor: Bionou Research, S.L. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New daily pill aims to stop HAE attacks, but trial cut short
Disease control TerminatedThis phase 2 trial tested KVD824, an oral pill, to prevent swelling attacks in people with hereditary angioedema types I and II. The study planned to compare three doses against a placebo over several months. However, the trial was terminated early with only 33 participants, so t…
Phase: PHASE2 • Sponsor: KalVista Pharmaceuticals, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New gel shows promise for vitiligo, but study halted early
Disease control TerminatedThis study tested a gel called VYN201 for people with non-segmental vitiligo, a condition that causes white patches on the skin. The goal was to see if the gel could reduce the size of these patches over 24 weeks. The trial involved 205 adults aged 18 to 75, but it was terminated…
Phase: PHASE2 • Sponsor: Vyne Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Promising drug for hand and foot blisters falls short in early trial
Disease control TerminatedThis study tested a daily pill called deucravacitinib in 3 adults with palmoplantar pustulosis (PPP), a painful skin condition causing blisters on palms and soles. The goal was to see if the drug could reduce disease severity by at least 50% over 24 weeks. However, the trial was …
Phase: PHASE4 • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Promising psoriasis drug trial halted early – what now?
Disease control TerminatedThis study tested a drug called imsidolimab for adults with generalized pustular psoriasis (GPP), a rare and painful skin condition. The trial aimed to see if the drug is safe and works over the long term. However, the study was terminated early, so we have less information than …
Phase: PHASE3 • Sponsor: Vanda Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New hope for vitiligo: experimental drug aims to restore skin color
Disease control TerminatedThis study tested an experimental drug called MK-6194 in adults with non-segmental vitiligo, a condition that causes white patches on the skin. The goal was to see if the drug could safely reduce the amount of vitiligo on the face compared to a placebo. The trial was stopped earl…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New drug hope for painful hand and foot pustules
Disease control TerminatedThis trial tested the drug deucravacitinib in people with moderate-to-severe palmoplantar pustulosis, a skin condition causing painful pustules on the palms and soles. The study planned to enroll 25 participants who would take the drug daily for 16 weeks, but it was terminated ea…
Phase: NA • Sponsor: Peking University First Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug shows promise for blistering skin disease in extended trial
Disease control TerminatedThis study looks at the long-term safety of a drug called efgartigimod for adults with moderate-to-severe bullous pemphigoid, a condition that causes painful blisters. Participants who finished the main study can continue treatment for up to 48 weeks, with the option to pause and…
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New pill for chronic hives and skin disease tested – but study halted early
Disease control TerminatedThis study tested an oral drug called INF904 in people with moderate to severe chronic spontaneous urticaria (long-term hives) or hidradenitis suppurativa (a painful skin condition). The trial was open-label and lasted 28 days of treatment plus follow-up. It aimed to check safety…
Phase: PHASE2 • Sponsor: InflaRx GmbH • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Hizentra shows promise for rare muscle and skin disease
Disease control TerminatedThis study tested a medicine called Hizentra (IgPro20) in 134 adults with dermatomyositis, a rare disease causing muscle weakness and skin rashes. The goal was to see if weekly shots under the skin could improve symptoms better than a placebo. The study was stopped early, but res…
Phase: PHASE3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New pill for eczema shows promise in early trial – but study halted
Disease control TerminatedThis study tested an oral medication called SAR444656 in 70 adults with moderate to severe atopic dermatitis (eczema) that was not well controlled with topical treatments. Participants received one of three doses of the drug or a placebo for 16 weeks. The goal was to see if the d…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New eczema drug shows promise in early trial
Disease control TerminatedThis study tested a new medicine called LY3454738 in adults with moderate-to-severe atopic dermatitis (eczema). The goal was to see if it could improve skin symptoms like redness and itching. The trial included 234 participants and was stopped early. Results may help understand i…
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Experimental drug XmAb27564 tested for skin conditions – trial halted early
Disease control TerminatedThis early-stage trial tested an experimental drug called XmAb27564 in 23 people with mild-to-severe plaque psoriasis or moderate-to-severe atopic dermatitis. Participants received four doses of the drug or a placebo every two weeks. The main goal was to check safety and tolerabi…
Phase: PHASE1 • Sponsor: Xencor, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Psoriasis combo therapy trial ends early: what happened?
Disease control TerminatedThis study tested whether adding low-dose methotrexate to standard anti-TNF therapy could improve and extend the response in adults with moderate to severe psoriasis. The trial planned to enroll 78 participants but was terminated early. The main goal was to see how long patients …
Phase: PHASE4 • Sponsor: Assistance Publique Hopitaux De Marseille • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Eczema drug trial halted early: what we know
Disease control TerminatedThis study tested an experimental drug called IMG-007 in 13 adults with moderate-to-severe atopic dermatitis (eczema) who did not get enough relief from topical treatments. The main goal was to check the drug's safety, and researchers also looked at how the body processes it and …
Phase: PHASE1, PHASE2 • Sponsor: Inmagene LLC • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Cream combo tested for scalp bumps in men of african descent
Disease control TerminatedThis study tested Duobrii, a prescription cream that combines a strong steroid with a retinoid, for treating early-mild acne keloidalis nuchae (AKN) — a chronic scalp condition causing bumps and scarring, mainly in men of African descent. The trial planned to enroll 15 adults wit…
Phase: PHASE3 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Spesolimab shows promise for Long-Term control of painful hand and foot pustules
Disease control TerminatedThis study looks at the long-term safety of spesolimab for people with palmoplantar pustulosis, a chronic skin condition causing painful pustules on hands and feet. Participants who benefited from spesolimab in earlier trials can continue treatment for up to 5 years, with monthly…
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New eczema drug abrocitinib tested in everyday use
Disease control TerminatedThis study looked at how well the drug abrocitinib works for adults with moderate to severe atopic dermatitis (eczema) in real-world clinics in Germany. Researchers tracked 112 participants for up to 12 months to see if their skin cleared or improved. The goal was to understand t…
Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New PET tracer aims to light up inflammation in joint and muscle diseases
Diagnosis TerminatedThis early-phase study tested a new radioactive imaging drug called 11C-MC1 to see if it can help detect inflammation in people with rheumatoid arthritis or idiopathic inflammatory myopathy, as well as in healthy volunteers. Participants received PET/CT scans after an injection o…
Phase: PHASE1 • Sponsor: National Institute of Mental Health (NIMH) • Aim: Diagnosis
Last updated Jun 26, 2026 18:25 UTC
-
Skin-Saving paste for cancer radiation falls short in tiny trial
Prevention TerminatedThis study tested whether Alkagin paste could prevent skin damage in patients receiving radiation for anal, rectal, or gynecological cancers. Only 2 people enrolled before the trial was stopped early. Because of this, we cannot draw any reliable conclusions about the paste's effe…
Phase: PHASE2 • Sponsor: Sir Mortimer B. Davis - Jewish General Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:32 UTC
-
Nail psoriasis injection study halted after just one person
Symptom relief TerminatedThis study tested whether injecting methotrexate directly into the nail area could improve nail psoriasis symptoms like pitting and discoloration. Only one person enrolled before the trial was stopped early. The goal was to measure changes in nail appearance using a severity scor…
Phase: PHASE4 • Sponsor: Weill Medical College of Cornell University • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
WaterPik for your head? study tests scalp massager for flakes and hair loss
Symptom relief TerminatedThis study tested a WaterPik-like device to massage and clean the scalp in people with dandruff, seborrheic dermatitis, or hair loss. Only 2 people took part before the study was stopped early. The goal was to see if the device could reduce flaking and redness.
Phase: NA • Sponsor: University of Minnesota • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
Laser zaps acne? small trial fizzles out
Symptom relief TerminatedThis study tested whether a fractional carbon dioxide laser can improve moderate to severe acne in adults aged 18 to 40. Participants received up to 3 laser treatments and were followed for changes in blemish count and skin severity. The trial was terminated early and only enroll…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Eczema cream study halted after just 3 volunteers
Symptom relief TerminatedThis small study tested an over-the-counter cream for atopic dermatitis (eczema) in just 3 people. Researchers looked at skin bacteria, hydration, and barrier function to see if the cream helped. The study was terminated early, so results are very limited.
Phase: PHASE1 • Sponsor: Good Molecules, LLC • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
New moisturizer combo tested for dry skin relief
Symptom relief TerminatedThis study tested whether a daily serum and cream could improve skin hydration and reduce redness in people with dry skin. Twenty-one adults applied the products for 14 days. The researchers measured skin moisture and redness before and after treatment to see if the products help…
Phase: NA • Sponsor: SCF Pharma • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Omega-3 skin cream shows promise for eczema relief in small study
Symptom relief TerminatedThis early study tested whether a daily omega-3 serum and cream could ease eczema symptoms and change the balance of bacteria on the skin. Seven adults with eczema applied the products for six weeks and reported their symptom severity using a questionnaire. The study also checked…
Phase: NA • Sponsor: SCF Pharma • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Psoriasis drug trial for sensitive areas halted early
Symptom relief TerminatedThis study tested the drug deucravacitinib (SOTYKTU) in 130 people with psoriasis on the palms, soles, and genitals. The goal was to see if it improves skin clearance and reduces symptoms. The trial was terminated early, so final results are limited.
Phase: PHASE4 • Sponsor: Bristol-Myers Squibb • Aim: Symptom relief
Last updated Jun 27, 2026 12:09 UTC
-
New eczema pill shows promise in Mid-Stage trial
Symptom relief TerminatedThis study tested an experimental daily pill called RPT193 for adults with moderate-to-severe atopic dermatitis (eczema) that didn't improve with topical creams. The goal was to see if it reduces skin redness, swelling, and itchiness over 16 weeks. The trial involved 229 particip…
Phase: PHASE2 • Sponsor: RAPT Therapeutics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Can a simple cream stop radiation burns? early trial halted
Symptom relief TerminatedThis study tested a cream called dermaprazole (a form of esomeprazole) to see if it could prevent or reduce skin burns caused by radiation therapy in women who had mastectomy for breast cancer. Only 3 women were enrolled before the trial was stopped early. The goal was to check s…
Phase: PHASE1, PHASE2 • Sponsor: Baylor College of Medicine • Aim: Symptom relief
Last updated Jun 27, 2026 09:06 UTC
-
New pill for stubborn hives shows promise, but trial halted early
Symptom relief TerminatedThis Phase 2 trial tested an experimental drug called EP262 in 113 people with chronic spontaneous urticaria (long-lasting hives with no clear cause). Participants took either EP262 or a placebo daily for 6 weeks, while continuing their usual antihistamines. The study aimed to se…
Phase: PHASE2 • Sponsor: Escient Pharmaceuticals, Inc • Aim: Symptom relief
Last updated Jun 27, 2026 08:05 UTC
-
Eczema cream aims to end sleepless nights
Symptom relief TerminatedThis study tested a prescription cream called ruxolitinib on adults with mild-to-moderate eczema who had trouble sleeping because of their condition. The goal was to see if the cream could help them sleep longer and better. The study was stopped early, but it involved 47 particip…
Phase: PHASE4 • Sponsor: Incyte Corporation • Aim: Symptom relief
Last updated Jun 27, 2026 08:05 UTC
-
Experimental shot for Cold-Triggered hives tested, but trial stopped early
Symptom relief TerminatedThis early-stage trial tested a single dose of a drug called briquilimab in 27 adults with chronic hives caused by cold or friction that did not improve with standard allergy pills. The main goal was to check safety and see if the drug could reduce symptoms. However, the trial wa…
Phase: PHASE1, PHASE2 • Sponsor: Jasper Therapeutics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 07:53 UTC
-
Cancer rash drug trial halted early – little known
Symptom relief TerminatedThis small, early-stage trial tested a drug called imsidolimab for treating acne-like skin rashes that can occur in cancer patients taking certain targeted therapies. Only 4 people were enrolled before the study was stopped. Because of the very small size and early termination, w…
Phase: PHASE2 • Sponsor: Vanda Pharmaceuticals • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
Skin microbes linked to vitiligo and immunotherapy reactions in melanoma patients
Knowledge-focused TerminatedThis study explores whether the community of bacteria living on the skin (the skin microbiome) plays a role in vitiligo—a condition that causes white patches—and in side effects from anti-PD-1 immunotherapy for advanced melanoma. Researchers will collect skin swabs from people wi…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Scientists hunt for blood clues to tame unpredictable swelling attacks
Knowledge-focused TerminatedThis study aimed to find biomarkers (measurable substances in the blood) that could help doctors diagnose bradykinin angioedema and predict how severe attacks might be. The condition causes sudden, unpredictable swelling, and current tests don't work well for all types. Researche…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Insulin's hidden role in psoriasis uncovered
Knowledge-focused TerminatedThis study looked at how insulin works in the skin of people with plaque psoriasis who are also overweight or have prediabetes. Researchers took small skin samples from both psoriasis patches and healthy skin to measure insulin activity. The goal was to understand if insulin acts…
Sponsor: Columbia University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC
-
Eczema Drug's skin secrets under the microscope
Knowledge-focused TerminatedThis study looked at how the drug tralokinumab affects the skin of people with moderate to severe atopic dermatitis (eczema). Researchers measured drug levels and immune changes in skin samples after 16 weeks of treatment. The goal was to better understand how the drug works, whi…
Phase: PHASE2, PHASE3 • Sponsor: University of Zurich • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Experimental eczema drug tested in healthy people – but trial halted
Knowledge-focused TerminatedThis was a very early (Phase 1) study to check the safety of an experimental drug called IPG7236, taken as a pill. The study involved 63 healthy adults aged 18 to 55. The goal was to see how the body handles the drug and if it causes side effects, before testing it in people with…
Phase: PHASE1 • Sponsor: Nanjing Immunophage Biotech Co., Ltd • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
Filmed consultations aim to decode eczema discomfort in babies under 6 months
Knowledge-focused TerminatedThis study filmed consultations between dermatologists and infants under 6 months old with atopic dermatitis (eczema). Researchers analyzed the videos to identify specific behaviors that might indicate discomfort, since standard itch assessment scales don't work for babies this y…
Phase: NA • Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Eczema study sheds light on skin disease and treatment options
Knowledge-focused TerminatedThis study aimed to better understand eczema by collecting data, blood, and skin samples from 69 participants across Canada. It also compared two types of light therapy (broadband vs narrowband UVB) to see which works better for treating eczema. The study was terminated early, so…
Phase: NA • Sponsor: Women's College Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC
-
Experimental eczema drug trial halted before results
Knowledge-focused TerminatedThis early-phase study aimed to test the safety of a new drug called LY3872386 in healthy volunteers and people with atopic dermatitis (eczema). The trial was terminated early, so no meaningful data on safety or how the body processes the drug were collected. Only 18 participants…
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC